1. Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo‐controlled trial (CAPTIVATE). Issue 5 (5th February 2023) Authors: Chang, Lin; Cash, Brooks D.; Lembo, Anthony; Kunkel, David C.; English, Brett A.; Lindstrom, Beatriz; Gu, Guibao; Skare, Sharon; Gilder, Kye; Turner, Stewart; Cataldi, Fabio; Lipkis, Donald; Tack, Jan Journal: Neurogastroenterology & motility Issue: Volume 35:Issue 5(2023) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗